Dr Pal walks us through research presented at the 2022 Genitourinary Cancers Symposium, including data from the TIVO-3 trial (NCT02627963) and findings from the NeoAvAx trial (NCT03341845) exploring avelumab (Bavencio) plus axitinib (Inlyta) for patients with high-risk, nonmetastatic clear-cell renal cell carcinoma.

S6 Ep47: Pal Discusses Eye-Catching ASCO GU Data in RCC

<p>In OncLive® On Air, you can expect to hear interviews with academic oncologists on the thought-provoking oncology presentations they give at the OncLive® State of the Science Summits. The topics in oncology vary, from systemic therapies, surgery, radiation therapy, to emerging therapeutic approaches in a particular type of cancer. This includes lung cancer, breast cancer, gastrointestinal cancers, hematologic malignancies, gynecologic cancers, genitourinary cancers, and more.</p>

Science

Health & Fitness

In OncLive® On Air, you can expect to hear interviews with academic oncologists on the thought-provoking oncology presentations they give at the OncLive® State of the Science Summits. The topics in oncology vary, from systemic therapies, surgery, radiation therapy, to emerging therapeutic approaches in a particular type of cancer. This includes lung cancer, breast cancer, gastrointestinal cancers, hematologic malignancies, gynecologic cancers, genitourinary cancers, and more.

Share S6 Ep47: Pal Discusses Eye-Catching ASCO GU Data in RCC

Sign up to save your podcasts

S6 Ep47: Pal Discusses Eye-Catching ASCO GU Data in RCC

S6 Ep47: Pal Discusses Eye-Catching ASCO GU Data in RCC

More shows like OncLive® On Air

Left, Right & Center

The Ben Shapiro Show

NEJM This Week

Nature Podcast

Research To Practice | Oncology Videos

ASCO Daily News

Audio Journal of Oncology Podcast

OncoPharm

ASCO Guidelines

The Uromigos

Simple English News Daily

Oncology Today with Dr Neil Love

People I (Mostly) Admire

Oncology Brothers: Practice-Changing Cancer Discussions

English Learning Podcast